A new drug called TDM-1 has now been shown to help HER2-positive locally advanced or
metastatic breast cancer patients who have previously undergone treatment with
Herceptin (trastuzumab) and taxane (Taxol/Taxotere) chemotherapy.
T-DM1 is composed of Herceptin in combination with DM1, a chemotherapy agent. It
targets the HER 2 molecule on the breast cancer cells and also delivers DM1 directly into those cells. The cells get hit by two different anti-cancer effects!
We are all anxiously awaiting FDA approval. Continue to check back with me and I will let you know as soon as TDM-1 is commercially available and what the trade name will be.
No comments:
Post a Comment